

**NLRP12 Antibody (N-term) Blocking peptide**  
**Synthetic peptide**  
**Catalog # BP14014a****Specification**

---

**NLRP12 Antibody (N-term) Blocking peptide - Product Information**Primary Accession [P59046](#)**NLRP12 Antibody (N-term) Blocking peptide - Additional Information****Gene ID** 91662**Other Names**

NACHT, LRR and PYD domains-containing protein 12, Monarch-1, PYRIN-containing APAF1-like protein 7, Regulated by nitric oxide, NLRP12, NALP12, PYPAF7, RNO

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody AP14014a was selected from the N-term region of NLRP12. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**NLRP12 Antibody (N-term) Blocking peptide - Protein Information****Name** NLRP12**Synonyms** NALP12, PYPAF7, RNO**Function**

Plays an essential role as an potent mitigator of inflammation (PubMed:[30559449](http://www.uniprot.org/citations/30559449)). Primarily expressed in dendritic cells and macrophages, inhibits both canonical and non-canonical NF-kappa-B and ERK activation pathways (PubMed:[15489334](http://www.uniprot.org/citations/15489334), PubMed:[17947705](http://www.uniprot.org/citations/17947705)). Functions as a negative regulator of NOD2 by targeting it to degradation via the proteasome pathway (PubMed:[30559449](http://www.uniprot.org/citations/30559449)). In turn, promotes bacterial tolerance (PubMed:[30559449](http://www.uniprot.org/citations/30559449)). Inhibits also

the RIGI- mediated immune signaling against RNA viruses by reducing the E3 ubiquitin ligase TRIM25-mediated 'Lys-63'-linked RIGI activation but enhancing the E3 ubiquitin ligase RNF125-mediated 'Lys-48'-linked RIGI degradation (PubMed:<a href="http://www.uniprot.org/citations/30902577" target="\_blank">30902577</a>). Acts also as a negative regulator of inflammatory response to mitigate obesity and obesity-associated diseases in adipose tissue (By similarity).

**Cellular Location**

Cytoplasm.

**Tissue Location**

Detected only in peripheral blood leukocytes, predominantly in eosinophils and granulocytes, and at lower levels in monocytes.

**NLRP12 Antibody (N-term) Blocking peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**NLRP12 Antibody (N-term) Blocking peptide - Images****NLRP12 Antibody (N-term) Blocking peptide - Background**

This gene encodes a member of the CATERPILLER family of cytoplasmic proteins. The encoded protein, which contains an N-terminal pyrin domain, a NACHT domain, a NACHT-associated domain, and a C-terminus leucine-rich repeat region, functions as an attenuating factor of inflammation by suppressing inflammatory responses in activated monocytes. Alternatively spliced transcript variants encoding distinct isoforms have been described but the full-length nature of some of these has not been determined.

**NLRP12 Antibody (N-term) Blocking peptide - References**

Bailey, S.D., et al. Diabetes Care (2010) In press : Cummings, J.R., et al. Tissue Antigens 76(1):48-56(2010) Talmud, P.J., et al. Am. J. Hum. Genet. 85(5):628-642(2009) Fahy, R.J., et al. Am. J. Respir. Crit. Care Med. 177(9):983-988(2008) Jeru, I., et al. Proc. Natl. Acad. Sci. U.S.A. 105(5):1614-1619(2008)